Enhancement of the therapeutic efficacy of mesenchymal stem cell-derived exosomes in osteoarthritis

Abstract

Osteoarthritis (OA), a common joint disorder with articular cartilage degradation as the main pathological change, is the major source of pain and disability worldwide. Despite current treatments, the overall treatment outcome is unsatisfactory. Thus, patients with severe OA often require joint replacement surgery. In recent years, mesenchymal stem cells (MSCs) have emerged as a promising therapeutic option for preclinical and clinical palliation of OA. MSC-derived exosomes (MSC-Exos) carrying bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins, have demonstrated a significant impact on the modulation of various physiological behaviors of cells in the joint cavity, making them promising candidates for cell-free therapy for OA. This review provides a comprehensive overview of the biosynthesis and composition of MSC-Exos and their mechanisms of action in OA. We also discussed the potential of MSC-Exos as a therapeutic tool for modulating intercellular communication in OA. Additionally, we explored bioengineering approaches to enhance MSC-Exos’ therapeutic potential, which may help to overcome challenges and achieve clinically meaningful OA therapies.

Development and characterization of osteoarthritis

Osteoarthritis (OA) is a progressively aggravating disease that can affect both small joints (such as hand joints) and large joints (such as knee and hip joints). Clinical symptoms of OA include knee pain, restricted movement, inflammation of the synovium, joint deformity, and even disability [1]. In fact, these clinical manifestations reflect various phenotypes of OA, including chronic pain phenotype, inflammatory phenotype, mechanical overload phenotype, minimal arthropathy phenotype, etc. [2]. The prevalence of OA is increasing year-over-year, with over 500 million people affected worldwide [3], and it ranks as the 11th most disabling disease in the world. According to statistics, about 9.6% of men and 18% of women over the age of 60 worldwide have symptomatic OA. Understanding the underlying mechanisms of OA will help to develop new treatments for future clinical needs.

While OA was once thought to be characterized primarily by the destruction of articular cartilage, recent evidence suggests that OA is a disease with whole joint damage and dysfunction [4]. During the progression of OA, pathological changes in the joint include cartilage damage, subchondral bone remodeling, inflammatory activation of the synovial membrane, and degeneration of periarticular tissues (connective and muscular tissues) and soft tissues (ligaments, tendons, and menisci) [5, 6]. A variety of factors contribute to pathological changes in OA joints [7], including aging, inflammation, trauma, oxidative stress, mechanical loading, and genetic and metabolic disorders (Fig. 1) [8]. The pathogenesis of OA involves various molecular pathways, such as protein hydrolysis/catabolic enzymes [e.g., matrix metalloproteinases (MMP), collagenases, and aggregated protein kinases], oxidation (superoxide and hydrogen peroxide), nitrosylation (nitric oxide and peroxynitrite) stress, inflammatory cytokines [interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α)], PGE2, cAMP, and many others, including transforming growth factor-β (TGF-β), c-Jun N-terminal kinase (JNK), and p38. Studies have revealed that certain miRNAs are associated with the development of OA [9], while other miRNAs are associated with the inhibition of OA [10,11,12,13]. Additionally, chondrocyte apoptosis plays an important role in the degeneration of OA articular cartilage [14, 15]. Subchondral bone, which is the cortical bone and trabecular bone structure beneath the articular cartilage, also plays an important role in the pathogenesis of OA, as it may contribute to cartilage degeneration through mechanical alterations or paracrine-mediated bone–chondral interactions [16]. Cytokines from inflammatory synovial fibroblasts (SFB) and infrapatellar fat pads (IPFP) may lead to the release of various proinflammatory mediators, which not only extensively alter synovial tissue structure and function, but also promote cartilage matrix damage and accelerate the development of OA [17, 18].

Fig. 1

Risk factors and pathological mechanisms of OA. Specific systemic risk factors (age, obesity, and sex) and mechanical factors (joint injury or overuse) can cause OA-like cartilage damage. Changes in the cartilage microenvironment, such as cellular secretion of matrix-degrading enzymes, reactive oxygen species, and cytokines, can accelerate the process of cartilage degeneration, resulting in the loss of the chondrocyte phenotype. The degradation products of cartilage and extracellular matrix (ECM) components can also be released into the joint cavity as damage-associated molecular patterns (DAMP) will boost the synovial cells and macrophages to secrete different types of inflammatory mediators. In addition, remodeling of the subchondral plate and calcified cartilage also reflects changes in the mechanical loading of cartilage and subchondral bone

Landscape of MSCs-mediated therapies in osteoarthritis

Current treatment options for OA have limitations. Traditional medical treatments only control symptoms and delay injury but cannot reverse the progression of OA. Thus end-stage degenerative joint diseases may require artificial joint replacement and osteotomy, but these procedures can result in serious complications such as postoperative stiffness, pain, thromboembolism, and prosthetic infection. The 10-year postsurgery risk of failure of total knee arthroplasty requiring revision surgery is 5% [19]. The rapid growth of cell transplantation and tissue regeneration methods for various diseases over the past few decades provides new avenues future for OA treatment. Figure 2 illustrates several of the most widely used cell transplant or cell-derived bioactive cargoes for cartilage repair. However, some methods, such as autologous chondrocyte implantation (ACI) or matrix-induced autologous chondrocyte implantation (MACI), have not been widely utilized for reasons such as the formation of fibrocartilage [20]. In contrast, MSCs have shown promise as ideal seed cells for the effective treatment of OA without the aforementioned drawbacks. MSCs are self-renewable pluripotent stem progenitor cells that can differentiate into various cell lines, including osteoblasts, adipocytes, and chondrocytes [21] [22]. MSCs can be induced to differentiate into chondrocytes and form cartilage matrix in a targeted manner, and they exhibit high therapeutic efficacy and safety due to their unique immunological properties. Allogeneic MSCs even have advantages over autologous bone marrow-derived MSCs (BM-MSCs) in clinical outcomes in elderly patients with reduced cartilage degeneration [23]. More specially, studies have found a high content of synovial fluid-derived MSCs (SF-MSCs) in the joint fluid of patients with OA [24]. Compared with the commonly used BM-MSCs, SF-MSCs have several advantages. They can be derived from medical wastes such as patients’ arthroscopic irrigation fluid and possess significantly higher chondrogenic differentiation capacity [25,26,27]. Furthermore, intraarticular injections of SF-MSCs have shown chondroprotection in an animal model of OA or articular cartilage defects [28,29,30,31]. Adipose tissue-derived MSCs (AD-MSCs) are another stem cell option for the treatment of OA. Adipose tissue has the advantages of being a wide source and having a better safety profile. Comparing the efficacy and safety of BM-MSCs and AD-MSCs in knee OA, AD-MSCs were shown to be more effective [32]. In addition, autologous sources such as endometrium [33] and peripheral blood (PB) [34], and allogenic sources such as placenta [35], umbilical cord [36], and amniotic fluid-derived MSCs [37] are accessible source of stem cells for OA treatment. We summarized the role of MSCs in the treatment of OA as shown in Table1.

Fig. 2

Current cell-based and cell-free therapies for osteoarthritis. Cell-based treatments for OA rely on regenerating injured cartilage while reducing ongoing inflammation in the affected joint. Autologous cultured chondrocytes based on ACI and MACI have been shown to be useful for cartilage tissue repair. MSCs are emerging as powerful self-renewal agents for osteoarthritis treatment. In addition, mesenchymal stem cell-derived exosomes (MSC-Exos) could replace MSCs and represent a novel cell-free therapy for OA

Table 1 Clinical trials of MSCs transplantation for knee OA

Apparently, MSCs from multiple sources have successfully moved toward the clinical trial stage for the treatment of OA. According to the follow-up results, MSCs showed positive results in the treatment of knee OA. In addition, these clinical trials have somewhat illustrated the biological safety of MSCs. However, while we vigorously promote MSCs toward the clinic to serve patients, we should also be aware of some of their possible risks. For example, the follow-up period of the current study is not long enough to predict whether MSCs will pose long-term biosafety problems. To obtain a sufficient amount of MSCs, patients may need to undergo multiple invasive procedures. And the renewal and differentiation capacity of MSCs declines due to the amplification process [38, 39].Therefore, there is an urgent need to develop effective agents that have the efficacy of MSCs as seed cells, while avoiding their potential risks, and could deliver relevant drugs for the treatment of OA cartilage degeneration.

Fundamental studies have shown that ability of MSCs to direct differentiation and paracrine secretion is the key factor to their therapeutic benefit in OA [47]. Direct differentiation into chondrocytes can play a reparative role by homing MSCs to the site of cartilage defects and proliferating and differentiating into functional cartilage or cartilage-like tissue. The process involves the recognition of chemokine ligands in the bone and joint fluid and binding to chemokine receptors (CXCR) on MSCs [48], thereby allowing MSCs to migrate to the damaged tissues [49]. Common chemokines such as the stromal derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) axis, osteopontin (OPN) has been used to help this “homing” process [50]. Of course, localized inflammation, degenerative lesions, and mechanical factors have also been shown to promote the homing of these stem cells to a damaged tissue [51]. As mentioned previously, MSCs have the ability to differentiate into chondrocytes. Since the natural regenerative capacity of cartilage is limited locally in OA, stem cell therapy is of great significance for cartilage regeneration in OA. The targeted differentiation of MSCs into chondrocytes is dependent on the local environment and signaling pathways. Cell–matrix interaction is a key factor influencing the biological response of MSCs, which are stimulated by the cartilage matrix to differentiate into the chondrocyte lineage after homing to the site of cartilage defects [52]. And in the OA microenvironment, transcription factors Sox9 and Runx2 and bone morphogenetic protein (BMP) signaling pathway regulate chondrogenesis [53] [54]. Apart from the fact that the differentiation of MSCs into chondrocytes is central to tissue repair, the paracrine mechanisms, however, are considered more important for the therapeutic effects of MSCs in OA. MSCs regulate local inflammation, apoptosis, and cell proliferation by secreting soluble factors and extracellular vesicles into the surrounding environment [55]. In summary, the mechanisms by which MSCs act on OA mainly rely on [1] homing to the site of cartilage defects, [2] chondrogenic differentiation to repair cartilage defects, and [3] paracrine secretion of tissue repair factors. Among the factors secreted by MSCs, the exosomes are involved in many physiological and pathological processes of OA. In recent years, the role and therapeutic potential of MSC-Exos in OA has received increasing attention.

In this review, we summarized the current state of research and major clinical challenges of using MSC-Exos in the treatment of OA and discussed bioengineering solutions to enhance MSC-Exos for the treatment of OA, with the hope of providing an important reference for developing more effective and predictable methods of using MSC-Exos for OA treatment.

Biogenesis and characterization of MSCs-derived exosomes

Exosomes are nanoscale extracellular vesicles with a diameter of 50–150 nm [56] and enclosed by a lipid bilayer. They originate from the endocytic pathway where endosomal membranes bud inward to the lumen to form intraluminal vesicles (ILVs). As early endosomes mature into late endosomal multivesicular bodies (MVBs), MVBs fuse with the plasma membrane to release ILVs/exosomes (Fig. 3) [57]. Exosomes undergo a series of regulatory processes that affect both the formation of exosome structure and cargo sorting. The endosomal sorting complex required for transport (ESCRT) pathway is the first pathway identified for exosome biogenesis. It consists of four protein complexes, namely ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III, as well as the proteins ALG-2-interacting protein X (ALIX), VTA1, and vacuolar protein sorting-associated protein 4 (VPS4). These ESCRT components assemble on the MVB membrane to regulate the assembly of cargoes and the formation of ILVs, promoting the formation and secretion of exosomes [58, 59]. In the endosomes, ESCRT-0, ESCRT-I, and ESCRT-II are responsible for recognizing ubiquitinated proteins and loading them into the lumen of the endosome [60]; ubiquitinated membrane proteins are recognized and incorporated into the MVB to participate in ILV formation, and non-ubiquitinated proteins are incorporated into the plasma membrane or Golgi complex [61]. Specifically, ESCRT-0 is involved in cargo aggregation and ubiquitination of endocytic receptors [62, 63], while ESCRT-I forms a complex with ubiquitinated proteins that activate ESCRT-II. Together, ESCRT-I and ESCRT-II complexes drive endosomal membrane bending to form ILVs [62, 63]. ESCRT-III is activated by ESCRT-II to recruit auxiliary proteins such as ALIX and VPS4, which together assist ILV formation in the MVB [59, 60]. Overall, the interplay among various ESCRT components allows cargo to be sequestered in ILVs and eventually excreted extracellularly to form exosomes. For ESCRT-independent pathways of exosome biogenesis, the neutral sphingomyelinase 2 (nSmase2) contributes to ceramide and sphingomyelinase hydrolysis, inducing MVBs to bud inward, and ceramide can cause the MVB membrane to spontaneously bend to form ILVs and eventually fuse with the cytosol to release exosomes [64]. However, tetraspanin proteins CD63 and CD81 also sort the associated proteins and ligands to ILVs [65, 66]. Other RAS-associated proteins Rab27A or Rab27B are indispensable to producing plasma membrane exosomes. Deletion of Rab27A or Rab27B alters the morphology of the MVB and affects its docking with the plasma membrane [67]. Various substances that are involved in the regulation of exosome biogenesis, such as ESCRT pathway-related components (TSG101 and ALIX), tetrapeptides (CD63, CD81, and CD9), membrane transport proteins (Rab proteins), and lipid components (ceramides), eventually become part of exosomes, conferring corresponding ligand effects, or becoming markers for identifying exosomes [68, 69].

Fig. 3

MSC-Exos: generation, structural composition, and protective effects on joint cartilage. MSC-Exos are nanoscale extracellular vesicles that originate from the inward budding of late endosomal membranes called MVBs and are released after fusion with the plasma membrane. The major components of MSC-released exosomes are lipid membranes rich in cholesterol, sphingomyelin, ceramide, and lipid raft proteins, which protect the contents from degradation or fusion with the membranes of target cells. In addition, exosomes of MSCs carry small nucleic acid molecules that play an important role in cartilage tissue regeneration, cartilage immunomodulation, and other processes

Exosomes are enriched not only in protein components but also in various types of nucleic acids, including mRNA, microRNA (miRNA), ribosomal RNA, long non-coding RNA (lncRNA), and DNA [70]. Despite accumulating evidence of the biological effects of exosomal nucleic acids, the loading mechanisms of these cargoes remain to be elucidated. Existing studies suggest that RNA encapsulation is closely related to RNA binding proteins (RBPs), with most RNAs being transferred from the nucleus to specific cellular sites associated with RBPs at the exosome biogenesis sites. RBPs serve as a bridge between RNA and exosome biogenesis [71, 72]. Typical RBPs such as heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1) are associated with exosome miRNA sorting [73], while studies have shown that miRNAs may be regulated by posttranscriptional modifications upon entry into exosomes [74]. In addition, RBPs regulate the enrichment of ncRNAs, short mRNAs, and mRNA fragments into exosomes [75]. Despite the knowledge that RBPs are important for RNA entry into exosomes, the mechanisms, such as the role of RBPs, specific RNA sequence motifs, and differential affinity for membrane lipids, still need to be elucidated in depth [76, 77]. However, there is an ambiguity in studies on DNA loading into exosomes, which is currently thought to be related to aging and DNA damage [78,79,80].

Enriched with various factors, exosomes become a means of exchanging molecular information for intercellular communication. Exosomes interact with receptor cells through their surface proteins and can fuse with the plasma membrane of receptor cells to release their contents, thus triggering signal transduction and ultimately affecting the function of the receptor cells [81]. MSC-Exos can be produced under both pathological and physiological conditions, and these exosomes can function similarly to MSCs themselves [82]. Recent studies have found that MSC-Exos can penetrate cartilage tissue as nanoscale transport vehicles and overcome tissue barriers for drug delivery into the dense articular cartilage matrix, which may provide a new means of treating cartilage tissue defects. We present a summary of studies on the role of extracellular vesicles in osteoarthritis in Table 2. By summarizing the previous reports, the potential of MSC-Exos for the treatment of OA in vitro and in vivo showed great promise. Studies on the use of MSC-Exos to delay OA progression or reverse progression toward OA have shown promising results. MSC-Exos can regulate chondrocyte proliferation, apoptosis, extracellular matrix degradation, and cartilage inflammation (Fig. 3) [83]. These studies observed that the MSC-Exos promote cartilage repair through a multifaceted mechanism involved in chondrocyte proliferation (MSC-Exos dose-dependent proliferation), increased infiltrative migration (migration of chondrocytes into the injured tissue), enhanced matrix synthesis (increase in type II collagen), attenuated apoptosis (increase in the anti-apoptotic gene BCL-2), inflammatory suppression (reduction of IL-1β and TNF-α), and immunomodulation (increase in M2 macrophages) [84]. A growing number of studies have confirmed the potential of MSC-Exos for the treatment of OA. Of course, the function of MSC-Exos as an important signaling mediator for intercellular communication involves complex contents and signaling pathways. We cover the discussion of related contents and mechanisms in the following table.

Table 2 Summary of the role of MSC-Exos role in osteoarthritis therapies

Exosomes/ncRNAs as mediating MSC-free based therapy of osteoarthritis

As previously discussed, exosomes can biogenetically sort various physiologically active substances, such as miRNA, mRNA, and proteins, which can be delivered to target cells and lead to significant changes in function and phenotype [20, 94]. These bioactive cargoes play a key role in intercellular communications during OA development [51]. Among these cargoes, exosome-miRNAs have been extensively studied in recent years. MiRNAs inhibit mRNA translation and splicing by binding to the non-coding regions of target mRNAs, which affect downstream pathways by blocking target gene expression [95,96,97]. Approximately 150 miRNAs are enriched in exosomes, and multiple miRNAs have key therapeutic benefits in OA [98]. Table 3 lists the most widely explored MSC-Exos miRNAs involved in OA. As shown in Table 3, a large number of studies have demonstrated the critical role of MSC-Exo-derived miRNAs in OA. By analyzing the targets of miRNAs, researchers identified multiple signaling pathways associated with OA. MiRNAs, as a small fraction of the contents in MSC-Exos, exhibit powerful biological efficacy. The signaling pathways of different miRNAs were synergizing to exert beneficial therapeutic effects on OA.

Table 3 MiRNAs known to involve in MSC-derived exosome-based osteoarthritis therapies

Besides miRNAs, lncRNAs have also shown therapeutic effects on OA. LncRNAs act as regulatory molecules by binding miRNA to mRNA binding sites, thereby reducing the expression of miRNA or mRNA [99]. Liu et al. found that overexpression of lncRNA-KLF3-AS1 in MSC-Exos effectively ameliorated IL-1β-induced chondrocyte injury. The lncRNA exerted a role of competing endogenous RNAs to suppress miR-206 expression, ultimately promoting cartilage repair [100]. Additionally, exosome-lncRNA MEG3 alleviates IL-1β-induced chondrocyte senescence and apoptosis, which explains its beneficial therapeutic effects on OA via BM- s [88]. Recent studies have shown that exosomal circRNAs represent a promising molecular sponge, competing for the regulation of miRNA expression, thus affecting a variety of diseases, including OA [101]. For example, exosomal circ-BRWD1 serves as a miR-1277 sponge to reduce chondrocyte viability and promote apoptosis, inflammation, and ECM degeneration via regulating TRAF6. This may provide a promising novel strategy for OA treatment [102]. Similarly, exosome-mediated knockdown of circ_0001846 regulates chondrocyte injury through a novel exosome/miR-149-5p/WNT5B pathway [103]. Understanding the important regulatory role of exosomal ncRNAs in osteoarthritis will provide novel therapeutic options for future clinical applications.

Immunoregulatory potential and antiinflammatory effects of MSC-Exos on OA

Synovial inflammation is a key feature of OA and involves various types of immune cells, including macrophages, T cells, and B cells, and their secreted inflammatory factors within the synovial fluid of affected patients [5]. Numerous studies have established the immunomodulatory potential of MSCs in inflammatory diseases such as OA [113,114,115]. As a paracellular secretory product, MSC-Exos are a safer and more effective means of regulating inflammation and immunity in the joint cavity of patients with OA. Previous studies have shown promising results that MSC-Exos exert anti-OA effects by regulating the biological behavior of macrophages. Shen et al. reported that the highly-expressed C–C chemokine receptor type 2 in exosome can bind to proinflammatory chemokine CCL2 and inhibit its activity, thus effectively preventing macrophage accumulation and inflammation [116]. In another study, the researchers found that MSC-Exos effectively inhibited the activation of the nod-like receptor pyrin domain 3 inflammasomes (NLRP3) in macrophages, which in turn decreased the release of proinflammatory factors such as IL-1β and IL-18, thereby effectively alleviating OA [116]. Moreover, MSC-Exos has a significant effect on M1/M2 polarization. The ability of exosomes to alter macrophage polarization can be developed for a variety of medical purposes [117]. Zhang et al. [84] have demonstrated that MSC-Exos can attract M2 macrophages to infiltrate OA joint cavities while reducing M1 macrophage infiltration, downregulating IL-1β and TNF-α expression, and effectively controlling OA progression. Other disease models have also been used to investigate MSC-Exos in driving M1 and M2 polarization and reducing inflammation [118]. Several studies have revealed that MSC-Exos-derived miRNAs play an essential role in regulating macrophage polarization [119, 120]. In addition, the regulation of T and B cells by MSC-Exos is also involved in inflammation. In vitro experiments have demonstrated that MSC-Exos can induce the conversion of T1 helper (Th1) cells to Th2 cells and inhibit the differentiation of T cells to Th17 cells, thus increasing the subpopulation of regulatory T cells (Tregs) [121]. This implies that MSC-Exos can decrease proinflammatory T helper cells Th1 [122] and Th17 [123], while Tregs act as immunomodulators that suppress immune responses and maintain immune tolerance by secreting cytokines such as TGF-β, IL-10, and IL-35, ultimately suppressing inflammation [124]. Studies on an in vivo arthritis model have shown that MSC-Exos effectively inhibits T-cell proliferation while inducing Treg proliferation, resulting in improved inflammatory progression. In contrast, MSC-Exos inhibit the terminal differentiation and maturation of plasma cells, possibly by inhibiting the expression of chemokine receptors on B cells, thereby suppressing their proliferation and reducing their chemotaxis [125]. Although MSC-Exos regulation of T and B cells in OA has yet to be fully understood, macrophage-related studies have demonstrated their important role in immune regulation, providing a new perspective for OA treatment.

Bioengineering solutions to enhance the innate functions of MSC-Exos toward osteoarthritis therapy

Preclinical animal studies have demonstrated promising responses for the use of MSC-Exos in the treatment of OA. However, the innate function of MSC-Exos is not always therapeutically adequate for disease treatment [126]. To maximize the targeted therapeutic efficacy of MSC-Exos, several bioengineering modification options should be explored to improve the innate function of MSC-Exos [94, 127,128,129,130]. Production of exosomes can also be optimized for process optimization, including the possibility of obtaining exosomes or biomimetic exosomes from three-dimensional (3D) culture [131]. In addition, 3D printing technology has gained increasing attention in recent years, and 3D printing-based tissue engineering strategies could be a novel solution to enhance the residence time and function of exosomes. Additionally, priming MSCs with hypoxia, cytokines, and small molecules has improved the therapeutic potential of MSC-exos.

Priming MSC-derived exosomes with TGF-β1

In particular, the growth factor TGF-β plays an important role in promoting the biological functions of MSC-Exos. Studies have shown that TGF-β1-stimulated MSC-Exos can promote cartilage repair. Alternatively, coculturing TGF-β1 with MSCs can upregulate the expression of miRNA-135b in MSC-Exos, which serves as a potent inhibitor to downregulate Sp1 protein, a class of transcription factors, which is associated with apoptosis. Researchers found that Sp1 can inhibits chondrocyte proliferation by upregulating the mouse collagen α1 (XI) gene [132]. Further investigations revealed that TGF-β1 exosome-treated murine chondrocytes displayed reduced Sp1 expression and enhanced cell viability, indicating that TGF-β1 downregulated Sp1 through MSC-Exo-derived miR-135b to improve the therapeutic outcome in an OA rat model [133]. Similarly, TGF-β1-modified MSC-Exo-derived miR-135b attenuated cartilage damage in OA rats by promoting M2 macrophage polarization [134]. In conclusion, priming MSCs with TGF-β1 can promote the function of MSC-Exos in promoting chondrocyte proliferation. In another study, TGF-β1 combined with BM-MSC-exos ameliorated articular cartilage degeneration, maintained local bone homeostasis, and alleviated pain, effectively mitigating disease progression in OA mice [135]. Therefore, the use of TGF-β1-enhanced exosomes for OA therapy represents a novel promising strategy.

Priming MSC-derived exosomes with TGF-β3 and KGN

TGF-β3 has been found to be more beneficial than TGF-β1 in stimulating cartilage formation [136]. Research has shown that MSC-Exos can promote the expression of chondrocyte surface markers aggrecan and type II collagen and reduce the expression of catabolic markers such as MMP-13 and ADAMTS5, and inflammatory markers such as iNOS. These effects can be further enhanced when BM-MSCs are preactivated with TGF-β3 [69]. However, TGF-β3 also promotes the expression of type X collagen genes during the late induction phase, leading to hypertrophy and eventually the formation of non-functional fibrocartilage rather than hyaline cartilage [136, 137]. In contrast, a novel small molecule compound KGN has been shown to inhibit TGF-β3-induced hypertrophy [138]. Therefore, priming BM-MSC-Exos with KGN (KGN-BMSC-Exos) was more effective in increasing the expression levels of GAG, COL-II, prg4, and SOX-9 compared with BM-MSC-Exos, suggesting that KGN-BMSC-Exos promote the synthesis of cartilage matrix [139]. Another study showed that costimulating rabbit SF-MSCs with KGN and TGF-β3 in vitro significantly increased the protein expression levels of type II collagen (COL II) and SRY-box 9 (SOX9) and decreased the expression level of type X collagen (COL X). These results demonstrated that the combined application of TGF-β3 and KGN can increase the expression of hyaline-like cartilage markers in vitro and improve the repair effect in vivo [29]. Overall, these results indicate that pretreatment of MSC-Exos with KGN and TGF-β3 represents another promising approach to enhance the therapeutic efficacy of MSC-Exos.

Gene transfection enhances the therapeutic effect of MSCs-derived exosomes

Achieving cost-efficiency in the production and acquisition of exosomes is crucial due to the time-consuming and expensive nature of the process. To address this issue, several studies have explored the transfection of the MYC gene into MSCs to enable large production of exosomes [140]. In one study, MSCs carrying MYC gene ensured an unlimited supply of cells, greatly increasing exosome production efficiency and reducing production costs [141]. Transfection of MSCs with a lentiviral vector containing the MYC gene has been shown to transform MSCs with delayed senescence and accelerated growth factor secretion, allowing for scale-up production of MSCs without senescence. As a result, transfected MSCs have been reported to secrete significant quantities of exosomes containing therapeutic factors, such as miR-92a-3p [90], lncRNA-KLF3-AS1 [86], miR-140-5p [111], and miR-320c [112], with notable therapeutic effects on OA. However, gene transfection has been controversial and they are still a long way entering into clinic trial. In particular, the MYC gene, as a class of protooncogenes, produces the most commonly activated oncoproteins in human cancers. Numerous studies have demonstrated that overexpression of MYC gene causes tumorigenesis [142]. Fortunately, in vitro studies have found that expression of MYC proteins in exosomes derived from MYC-transfected MSCs can not detected, thus the risk of carcinogenicity of the collected exosomes was greatly reduced [141]. Although it is unlikely that MYC-transformed MSCs can be used for clinical applications at this time, in vitro use for larger production of exosomes seems to be a strategy that deserves further investigation. New gene editing tools such as CRISPR/ Cas9 can also be used to enhance the function of exosomes, and it is believed that similar gene-edited exosomes will be available as novel way to change the therapy function [143,144,145,146].

Three-dimensional cultures enhance the therapeutic capacities of MSC-derived exosomes

The productivity of exosomes can be continuously and efficiently increased by using the 3D culture technique. Many studies have compared the size, content, function, and production efficiency of exosomes in 2D and 3D cultures. The results clearly and consistently demonstrated that exosomes cultured in 3D have superior productivity and therapeutic effects than those cultured in 2D [147]. In multicellular organisms, cells are highly organized by the extracellular matrix in a 3D manner, while 2D cultures lack the spatial polarization and structures found in vivo, leading to alterations in exosome morphology, contents, and functions [148]. To obtain meaningful results, researchers have prepared 3D scaffolds using cell-free cartilage extracellular matrix to produce more exosomes, which resulted in stronger cartilage repair in a rat model of knee cartilage defect [149]. In addition, collecting exosomes by 3D-culturing MSCs can maintain the MSCs phenotype and produce exosomes with higher therapeutic efficiency [26, 150]. For example, Cao et al. [151] showed that a 3D culture system increased the total yield of MSC-Exos by 19.4-fold, with higher production efficiency and excellent antiinflammatory effects. Therefore, 3D culture technology may be a promising method to improve the secretion of MSC-Exos for the treatment of OA.

MSC-exosome-laden scaffolds for enhancing osteoarthritis cartilage tissue repair

In recent years, some natural or polymeric biomaterials have gained widespread use in cartilage repair and regeneration. These biomaterial-based scaffolds provide mechanical and 3D structure support, facilitating cell adhesion, migration, and differentiation in vivo [152, 153]. For OA, cartilage defect repair has been a challenging task, and the use of scaffold materials may enable ideal cartilage defect repair outcomes. Scaffold materials can be used as ideal patches to fill in cartilage defects and retain MSC-Exos at the cartilage defect site, ensuring precise and prolonged biological effects that induce cartilage repair and reverse OA progression [154, 155].

Hydrogels are one of the preferred scaffold materials due to their high water content, biocompatibility, swelling behavior, and adjustable 3D network [156]. Liu et al. revealed the superior efficacy of photo-induced imine cross-linked hydrogels as exosome scaffolds in repairing OA. These composite scaffolds have excellent cartilage integration, can bind to natural cartilage matrix, and promote cell deposition at the cartilage defect site. Furthermore, MSC-Exos could be retained long-term with the scaffolds’ support, ultimately promoting cartilage defect repair [157]. In another study, 3D-printed cartilage ECM/gelatin methacrylate (GelMA) scaffolds were used to support exosomes. The scaffolds were evaluated in a rabbit OA model, and the results showed that the ECM/GelMA/exosome scaffolds effectively repaired chondrocyte mitochondrial dysfunction, promoted cartilage cell migration, and differentiated synovial macrophages toward the M2 phenotype [158]. Jiang et al. used cell-free cartilage extracellular matrix (ACECM) scaffold loaded with human umbilical cord Wharton lyophilized cell exosomes (hWJMSC-Exos) and found it enhanced the effect of the ACECM scaffold, demonstrating a superior prochondrogenic effect in a rabbit knee osteochondral defect repair model [159]. Overall, the scaffold materials loaded with MSC-Exos have significant potential for enhancing cartilage repair and improving the inflammatory environment of the joint cavity, providing a potent and predictable therapeutic strategy for OA.

Conclusions and prospects

Although the immunomodulatory and regenerative properties of MSCs have demonstrated their potential in OA therapies, challenges such as sourcing, culture condition, preservation, and possible host conflicts after transplantation remain. However, the study of the functions of MSC-generated exosomes has revealed their great potential for the treatment of OA. MSC-Exos are considered a key factor for their small size, stability, biological activity, and targeting property in the treatment of OA. To further expand the therapeutic scope of MSC-Exos beyond their inherent functions, engineering approaches can significantly improve the efficacy of clinical OA indications. For example, pretreating MSCs with substances such as TGF-β1, TFG-β3, and KGN and establishing a rational 3D culture microenvironment to promote exosome production and functional enhancement can increase the potency of MSCs. Strategies such as the use of biomaterials can help localize exosome injections directly to the damaged target site for long-lasting effects [160]. Future studies should explore the utilization of large animal models to better mimic OA conditions and clinical dosing regimens. However, before we discuss the clinical translation of exosome therapy for OA, it is necessary to explore the current progress of clinical translation of MSC-derived extracellular vesicles (MSC-EVs), which can give researchers and patients new therapeutic strategies and the direction for future research. EVs are cargo-carrying vesicles, including exosomes, that are released by cells into the extracellular space [161]. In particular, MSC-secreted EVs can show comparable biological effects out of parental cells and exhibit more stability and safety, thus researchers have exploited a lot of efforts for clinical application [162, 163]. According to the registered projects of the clinical trials database, they are about studies on MSC-EVs, with more than 3000 subjects expected to receive MSC-EVs for a variety of diseases, including acute respiratory distress syndrome [164, 165]. These clinical trials have given new potential for the treatment of patients in the corresponding fields, especially exosome-based therapy for OA.

Although we have proposed many of the advantages of exosomes, the current research on exosome therapy for OA is limited to the preclinical animal phase. Two technical obstacles mainly limit the application of exosomes—on the one hand, current technology makes it difficult to obtain exosomes in a simplified and high yield; on the other hand, efforts are still needed to efficiently isolate functional exosomes [166]. In the above discussion, we illustrated examples of exosome yield enhancement through bioengineering, genetic, and 3D technologies, which indicate the direction of future technological breakthroughs. However, all currently used techniques for exosome isolation have corresponding drawbacks, and none of them can be standardized [167]. Even specific exosomes hide numerous problems due to the wrapping of various complex molecules, including the uncontrollability of the effects produced by unknown molecules and the quantification of miRNA, lncRNA, and circRNA in MSC-Exos [168]. In addition, there is still a lack of pharmacokinetics and biodistribution of exosomes in vivo [169, 170]. Undeniably, several organizations, including the International Society for Extracellular Vesicles, are try to develop guidelines for MSC-Exos for the treatment of OA [171]. As work continues, the resolution of issues such as idealized sources of exosome, standardized access, delivery routes, dosing, and dosing frequency is key to bringing exosome therapy for OA into the clinic setting [168].

It is believed that exosomes will play a greater role as the next generation of “mesenchymal stem cell therapy” in treating OA. One day, MSC-Exos for OA will again clinically benefit humanity.